HK1120223A1 - Reducing post-operative adhesion formation with intraperitoneal glutamine - Google Patents

Reducing post-operative adhesion formation with intraperitoneal glutamine

Info

Publication number
HK1120223A1
HK1120223A1 HK09100189A HK09100189A HK1120223A1 HK 1120223 A1 HK1120223 A1 HK 1120223A1 HK 09100189 A HK09100189 A HK 09100189A HK 09100189 A HK09100189 A HK 09100189A HK 1120223 A1 HK1120223 A1 HK 1120223A1
Authority
HK
Hong Kong
Prior art keywords
glutamine
patient
adhesion formation
peritoneum
reducing post
Prior art date
Application number
HK09100189A
Other languages
English (en)
Inventor
Adebola O E Obayan
Original Assignee
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saskatchewan filed Critical Univ Saskatchewan
Publication of HK1120223A1 publication Critical patent/HK1120223A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/145—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/21—Acids
    • A61L2300/214—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
HK09100189A 2005-08-11 2009-01-08 Reducing post-operative adhesion formation with intraperitoneal glutamine HK1120223A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70717305P 2005-08-11 2005-08-11
PCT/CA2006/001319 WO2007016791A1 (fr) 2005-08-11 2006-08-11 Réduire la formation d’adhérences post-opératoires par le biais de glutamine intrapéritonéale

Publications (1)

Publication Number Publication Date
HK1120223A1 true HK1120223A1 (en) 2009-03-27

Family

ID=37727066

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09100189A HK1120223A1 (en) 2005-08-11 2009-01-08 Reducing post-operative adhesion formation with intraperitoneal glutamine

Country Status (15)

Country Link
US (5) US20100260819A1 (fr)
EP (1) EP1940439B1 (fr)
JP (1) JP5194207B2 (fr)
AT (1) ATE485829T1 (fr)
AU (1) AU2006279218B2 (fr)
CA (1) CA2618600C (fr)
CY (1) CY1112051T1 (fr)
DE (1) DE602006017864D1 (fr)
DK (1) DK1940439T3 (fr)
ES (1) ES2355159T3 (fr)
HK (1) HK1120223A1 (fr)
PL (1) PL1940439T3 (fr)
PT (1) PT1940439E (fr)
SI (1) SI1940439T1 (fr)
WO (1) WO2007016791A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1940439B1 (fr) 2005-08-11 2010-10-27 University Of Saskatchewan Réduire la formation d adhérences post-opératoires par le biais de glutamine intrapéritonéale
CA2578647A1 (fr) * 2007-02-15 2008-08-15 University Of Saskatchewan Reduction de la formation d'adherences post-operatoires par le biais de glutamine intraperitoneale
WO2008106702A1 (fr) 2007-03-02 2008-09-12 Zytoprotec Gmbh Liquide de dialyse péritonéale à base d'hydrate de carbone, comprenant un résidu de glutamine
US20100082113A1 (en) * 2008-04-29 2010-04-01 Peter Gingras Tissue repair implant
BR112012033349A2 (pt) * 2010-06-28 2016-10-11 Adetherapeutics tratamento de queloide
EP2839851A4 (fr) 2012-08-16 2015-11-25 Nipro Corp Matière anti-adhésive
CA3019841A1 (fr) 2016-04-29 2017-11-02 The Board Of Trustees Of The Leland Stanford Junior University Procedes et compositions pour la prevention et le traitement d'adherences chirurgicales
CN109789249B (zh) 2016-06-15 2022-01-25 土耳其科学技术研究理事会 多功能疝气贴片
US10500318B1 (en) * 2018-07-03 2019-12-10 Temple Therapeutics BV Dosing regimens for treating hypoxia-associated tissue damage
CA3217400A1 (fr) * 2021-05-07 2022-11-10 Nilabh GHOSH Procedes de traitement de la fibrose et de lesions associees a l?hypoxie a des nerfs peripheriques

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0426857A4 (en) * 1989-02-08 1991-10-16 Kuraray Co. Ltd. Peptide and adsorbent comprising same immobilized on carrier
US5248697A (en) 1990-09-20 1993-09-28 Brigham And Women's Hospital Enhancement of glutathione levels with glutamine
CA2114290C (fr) * 1993-01-27 2006-01-10 Nagabushanam Totakura Dispositif anti-adhesif post-chirurgical
US5425740A (en) * 1994-05-17 1995-06-20 Hutchinson, Jr.; William B. Endoscopic hernia repair clip and method
US6965014B1 (en) * 1996-01-16 2005-11-15 Baxter International Inc. Fibrin material and method for producing and using the same
US6280745B1 (en) * 1997-12-23 2001-08-28 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
GB9609993D0 (en) 1996-05-14 1996-07-17 Norbrook Lab Ltd Oral rehydration product
US6797729B1 (en) * 1996-06-28 2004-09-28 Baxter International Inc. Therapeutic glutamine and N-actyl-cysteine composition
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
JP2001513559A (ja) * 1997-08-25 2001-09-04 ブレム，ハロルド 新脈管形成インヒビターを用いる癒着および過剰な瘢痕形成の予防
EP1087998A1 (fr) * 1998-06-16 2001-04-04 Biogen, Inc. Proteines de fusion d'un variant du recepteur du type ii du tgf-beta et leurs methodes d'utilisation
JP2002521423A (ja) 1998-07-31 2002-07-16 コリア インスティチュート オブ サイエンス アンド テクノロージ 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子
US6613070B2 (en) * 1998-08-04 2003-09-02 Baxter International Inc. System and method for sealing vascular penetrations with hemostatic gels
US20030007951A1 (en) 2000-08-23 2003-01-09 Richard Franklin Treatment of trauma
NZ539139A (en) * 2002-10-08 2007-11-30 Abbott Lab Methods and compositions for providing glutamine
US7148199B2 (en) * 2003-09-26 2006-12-12 University Of Florida Research Foundation, Inc. Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation
EP1940439B1 (fr) 2005-08-11 2010-10-27 University Of Saskatchewan Réduire la formation d adhérences post-opératoires par le biais de glutamine intrapéritonéale

Also Published As

Publication number Publication date
CY1112051T1 (el) 2015-11-04
WO2007016791A8 (fr) 2008-09-18
AU2006279218A1 (en) 2007-02-15
US20190111189A1 (en) 2019-04-18
US20150250928A1 (en) 2015-09-10
JP5194207B2 (ja) 2013-05-08
DE602006017864D1 (de) 2010-12-09
US20170203013A1 (en) 2017-07-20
US10799622B2 (en) 2020-10-13
DK1940439T3 (da) 2011-02-14
PL1940439T3 (pl) 2011-04-29
ES2355159T3 (es) 2011-03-23
EP1940439A4 (fr) 2009-07-08
AU2006279218B2 (en) 2013-05-02
EP1940439A1 (fr) 2008-07-09
US20100260819A1 (en) 2010-10-14
EP1940439B1 (fr) 2010-10-27
JP2009504576A (ja) 2009-02-05
US9011883B2 (en) 2015-04-21
ATE485829T1 (de) 2010-11-15
SI1940439T1 (sl) 2011-02-28
PT1940439E (pt) 2010-12-17
US20130171209A1 (en) 2013-07-04
WO2007016791A1 (fr) 2007-02-15
CA2618600C (fr) 2017-05-02
CA2618600A1 (fr) 2007-02-15

Similar Documents

Publication Publication Date Title
HK1120223A1 (en) Reducing post-operative adhesion formation with intraperitoneal glutamine
MX342613B (es) Geles con base de acido hialuronico que incluyen agentes anestesicos.
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
EP2238982A3 (fr) Agent thérapeutique pour sarcome des tissus mous
WO2008073670A3 (fr) Formulations de doses unitaires et procédés de traitement d'une thrombose avec un inhibiteur oral du facteur xa
WO2007134678A3 (fr) Dérivés de triazole ii
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
MX2010007295A (es) Composiciones acuosas estables de ciclosporina.
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
PL1888013T3 (pl) Biologicznie przyswajalne wypełniacze składające się z liposomów fosfolipidowych i kwasu hialuronowego i/lub jego pochodnych
TW200640441A (en) Prevention and treatment of thromboembolic disorders
MX2007005509A (es) Composicion y viscoelastica de polimero natural triple.
HK1099918A1 (en) Composition and use for prevention or treatment of stomatitis
TNSN08506A1 (en) Substituted carboxamides
WO2007133796A3 (fr) Procédés et compositions de traitement de l'apnée du sommeil
WO2010037864A3 (fr) Inhibition du plgf pour traiter les leucémies à chromosome positif philadelphia
ATE501719T1 (de) Methoden und zusammensetzungen zur beruhigung von mund- und nasenschleimhäuten
WO2007024810A3 (fr) Compositions et procedes permettant de traiter les plaies et de reduire la formation de cicatrices
NZ533483A (en) Combinations of viscoelastics for use during surgery
WO2007047893A3 (fr) Utilisation de dasatinib dans le traitement de metastase osseuse
GEP20063822B (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
RS51420B (en) HYPERSTRUCTURE AMYLOPECTIN FOR USE IN THE PROCEDURES OF SURGICAL OR THERAPEUTIC TREATMENT OF mammals OR IN THE PROCEDURES OF DIAGNOSIS, AND PARTICULARLY FOR USE AS A PLASMA VOLUME EXPANDER
MX2009003384A (es) Agente terapeutico y/o de mejoramiento para la coagulacion intravascular diseminada.
WO2009090240A3 (fr) Utilisation du facteur viia ou d'équivalents du facteur viia pour prévenir ou atténuer une évolution hémorragique et/ou la génération d'un œdème à la suite d'une hémorragie intracérébrale (ich) chez une sous-population sélectionnée de patients ich